Topline Findings
- Pharma workforce reductions intensify: Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals announce significant layoffs to focus on core clinical programs and extend cash runways.
- Strategic reprioritization drives decisions: Companies are cutting discovery research and non-critical operations to allocate resources toward late-stage clinical milestones and high-priority programs.
- Industry-wide trend continues: Major biopharma players, including Bayer, Merck, and Moderna, previously announced layoffs to reduce costs and streamline operations amid challenging market conditions.
Are Pharma Layoffs Signaling a Broader Industry Shift?
Adding to a growing wave of workforce reductions across the pharmaceutical industry, Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals are the latest companies to announce significant layoffs this quarter. The moves aim to streamline operations, focus resources on their most advanced clinical programs, and extend cash runways while advancing key clinical programs.
Fate Therapeutics Layoffs
Fate Therapeutics is decreasing its workforce by approximately 12% as part of a tactical operations plan designed to extend its cash runway through 2027. The company said the reduction will help prioritize its iPSC-derived CAR T-cell programs, optimize resource allocation, and support key clinical and collaboration milestones across its pipeline.1
“Operationally, we have taken proactive steps to optimize our resource allocation and extend our cash runway, positioning us well to continue executing across our pipeline, working to bring transformative off-the-shelf cellular immunotherapies to patients with unmet needs,” said Bob Valamehr, PhD, MBA, president, CEO, Fate Therapeutics, in a press release.
Generation Bio Layoffs
Generation Bio plans to reduce its workforce by 90% between mid-August and the end of October 2025, including its R&D organization. The move is part of a strategic review exploring potential mergers, acquisitions, or other transactions while maintaining core research capabilities, according to the company. The restructuring is intended to preserve its most critical programs, including its experimental T cell-targeted genetic medicine platform, which recently showed promising early data in non-human primates. In these studies, Generation Bio’s cell-targeted lipid nanoparticle (ctLNP) system successfully delivered siRNA selectively to T cells, achieving significant knockdown of beta-2 microglobulin without activating the cells, underscoring the technology’s potential as the company explores strategic alternatives.2
“Our team has delivered exceptional work marked by rigor, creativity, and a deep commitment to our mission,” said Geoff McDonough, MD, CEO, Generation Bio, in a press release. “They have consistently driven ctLNP and iqDNA advances that could serve as a foundation for progress for patients going forward.”
ORIC Pharmaceuticals Layoffs
ORIC Pharmaceuticals reduced its workforce by 20% as part of a strategic reprioritization to focus exclusively on its two lead clinical programs, ORIC-944 in prostate cancer and enozertinib in non-small cell lung cancer. The company is discontinuing discovery research to concentrate resources on advancing these programs toward potential Phase III trials in 2026.3
“As our clinical programs have progressed closer to registrational studies, it necessitates that we increase our focus and direct our expenditures solely on those programs, and so we’ve made the tough, but prudent, decision to substantially reduce our investment in discovery research,” said Jacob M. Chacko, MD, president, CEO, ORIC Pharmaceuticals, in a press release. “This reprioritization and additional financing further extend our cash runway into the second half of 2028. It’s with a heavy heart that we say goodbye to our colleagues impacted by the resulting workforce reduction. We are grateful for their many contributions to ORIC, we’re deeply sorry for the upheaval they are experiencing, and we sincerely hope to honor them by advancing our clinical pipeline to benefit patients as rapidly as possible.”
How Many Pharma Firms Have Announced Layoffs Recently?
- These layoffs represent a growing trend of workforce reductions sweeping the pharmaceutical industry, underscoring the sector’s efforts to cut costs and sharpen focus on high-priority clinical programs amid the threat of pharmaceutical tariffs from President Trump.
- Last week, Bayer announced it had laid off approximately 12,000 employees to date as part of a restructuring led by CEO Bill Anderson, aiming to achieve $2.3 billion in annual savings by 2026 with a focus on reducing managerial roles.4
- Earlier this month, Merck and Moderna also announced workforce reductions.
- Merck plans to cut 3,000 jobs as part of a broader cost-saving initiative aimed at reducing annual expenses by $3 billion by the end of 2027.
- Moderna announced a global reduction of approximately 10%, targeting a total workforce of fewer than 5,000 employees by year-end.5,6
“This decision was not made lightly,” said Stéphane Bancel, CEO, Moderna, in a letter to employees earlier this month. “It impacts teammates and friends who have dedicated themselves to our mission and who have helped build Moderna. I want to express, on behalf of the entire Executive Committee and on behalf of patients you have served, our deepest thanks for everything you have contributed.”
References
- Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates. Fate Therapeutics. August 12, 2025. Accessed August 14, 2025. https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-second-quarter-2025-financial-results
- Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results. GlobeNewswire. August 12, 2025. Accessed August 14, 2025. https://www.globenewswire.com/news-release/2025/08/12/3132126/0/en/Generation-Bio-Announces-New-Data-for-Its-Novel-ctLNP-Delivery-System-and-Early-T-Cell-Programs-and-Reports-Second-Quarter-2025-Financial-Results.html
- ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates. GlobeNewswire. August 12, 2025. Accessed August 14, 2025. https://www.globenewswire.com/news-release/2025/08/12/3132137/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Updates.html
- Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan. PharmExec. August 7, 2025. Accessed August 14, 2025. https://www.pharmexec.com/view/bayer-layoffs-12-000-ongoing-2-3-billion-restructuring-plan
- Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027. PharmExec. August 1, 2025. Accessed August 14, 2025. https://www.pharmexec.com/view/merck-cut-6-000-jobs-3-billion-cost-savings-2027
- Moderna to Reduce Workforce by 10% Amid Cost Restructuring. PharmExec. August 1, 2025. Accessed August 14, 2025. https://www.pharmexec.com/view/moderna-reduce-workforce-10-cost-restructuring
